Eli Lilly Therapeutic 3 - Product Scorecard

Company: Eli Lilly

Type: Covid-19 Therapeutic
Product (brand name): Baricitinib (Olumiant)
0%
compliance
with criteria
Share this score on social:

Other company scores

Bharat Biotech Vaccine
0%
Brii BioSciences Therapeutic
0%
CanSino Vaccine
0%
Celltrion Therapeutic
0%
CIGB Vaccine
0%
Texas Children’s Hospital Vaccine
0%
Finlay Vaccine
0%
Gamaleya Vaccine
0%
Gilead Therapeutic
0%
Johnson & Johnson Vaccine
0%
Moderna Vaccine
0%
Vaxine Vaccine
0%
Vektor Vaccine
0%
Zydus Vaccine
0%
AstraZeneca Antibody
0%
AstraZeneca Vaccine
0%
Eli Lilly Therapeutic 3
0%
Eli Lilly Therapeutic 2
0%
Eli Lilly Therapeutic 1
0%
MSD Therapeutic
0%
Novavax Vaccine
0%
Pfizer Therapeutic
0%
Pfizer Vaccine
0%
Regeneron Therapeutic
0%
Roche Therapeutic
0%
Sanofi Vaccine
0%
Sinopharm Vaccine
0%
Sinovac Vaccine
0%
GSK Therapeutic
0%
Explore the results of PAF’s research into the behaviour of Eli Lilly. Each section is given an overall score; individual criteria are also scored (see icon following the criteria heading).

Click on ‘Explanation about the score’ sign next to each entry to expand and learn more.

Category A: Commitments and Accountability

The company should publicly commit to human rights in relation to product development and marketing, by adopting an official human rights policy statement recognising the right to the highest attainable standard of health. The company should endeavour to integrate human rights into its strategies, policies, programmes, projects, and activities.

The company should also have a publicly available global access plan for their Covid-19 product, based on human rights standards, with measurable targets and lines of accountability.

A1: Does Eli Lilly publish a global access plan for its product?

Eli Lilly has made a general commitment to equitable access to medicines in low- and middle-income countries.

It has also published ‘Principles of Covid-19 antibody therapy pricing and access’, and an Infographic on access and affordability principles for neutralizing antibodies.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
A2: Does Eli Lilly commit to comply with human rights standards in relation to product development and marketing?

Eli Lilly has not published a commitment to comply with human rights.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody

Category C: International cooperation

The company should constructively engage with international initiatives for the equitable distribution of vaccines and therapeutics, such as the Covid-19 Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP), and the ACT Accelerator (COVAX). The company should also publicly commit to not enforcing the exclusive rights of Covid-19 related patents, and enter into non-exclusive, transparent licensing agreements for its Covid-19 products with other companies.

C1: Does Eli Lilly commit to C-TAP or MPP?

Eli Lilly has not committed to C-TAP or the MPP.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
C2: Does Eli Lilly commit to not enforcing the exclusive rights of Covid-19 related patents?

Eli Lilly has not made a commitment not to enforce patents: ‘Eli Lilly [has] filed and obtained patents widely, including in countries hit hard by the pandemic, such as Brazil, Russia, South Africa and Indonesia. Where patents are granted, the monopoly does not expire until 2029 and could even persist longer because of patent-term extensions’. 

Eli Lilly states on its website: Olumiant is patent-protected in the USA until 2030; in Europe until 2029 and Japan until 2033. 

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
C3: Does Eli Lilly supply to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator?

Eli Lilly has not signed an agreement with the ACT Accelerator.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
C4: Does Eli Lilly agree to license its Covid-19 medical products to other companies?

Eli Lilly has signed deals with Indian generic manufacturers for royalty-free voluntary licensing agreements (Cipla, Natco pharma, Doctor Reddy’s, Sun Pharma, Lupin, Torrent and BDR). 

Note: the geographical scope of Lilly’s licensing policy is limited to India, which greatly restricts its impact. While the voluntary nature of Lilly’s licenses is good, broader licensing territories have a greater impact on global access.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody

Category E: Equality, non-discrimination & equity

The company should engage in efforts to further equitable distribution of Covid-19 vaccines/therapeutics, by equitably distributing its supplies globally, devising fair pricing strategies, and making the active ingredient for its product available to other manufacturers. The company should also engage in full technology transfer to other manufacturers, including the necessary transfer of skills, legal components, knowledge and intellectual property. Where applicable, the company should agree to waive rights in regulatory test data, and refrain from enforcing TRIPS+ measures.

E1: Does Eli Lilly make the active ingredient available on reasonable grounds? [Only for therapeutics]

There is no evidence that Eli Lilly makes the active ingredient for Baricitinib available to other manufacturers (there is only one supplier of the generic ingredient Baricitinib)

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
E2: Does Eli Lilly commit to full technology transfer to other manufacturers?

Eli Lilly has entered into non-exclusive licensing agreements with Indian manufacturers but there is no evidence of full technology transfer.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sinopharm Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic